載入中
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
前收盤價
US$99.87
+US$5.61 · +5.95%
盤前
US$100.49
+US$0.62 · +0.62%
10月12日 上午4:36 ET
盤中時間採用ET。市場資料可能有所延遲。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日內區間
目前US$99.87
52週區間
目前US$99.87
盤中時間採用ET。市場資料可能有所延遲。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日內區間
目前US$99.87
52週區間
目前US$99.87
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$98.40
下跌空間 1.47%報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1.22億1.24%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM9815.36萬0.13%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI4818.83萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Biotechnology ETFIBB4247.58萬0.40%108.2億 USD0.44%US$206.49+3.00%
iShares Russell 2000 Growth ETFIWO3431.05萬0.25%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA1983.85萬0.09%218.24億 USD0.03%US$32.79+0.40%
Vanguard Extended Market ETFVXF1784.69萬0.02%954億 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM1449.63萬0.22%64.1億 USD0.28%US$45.46+0.46%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
